Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 10/20 | 0.54 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM1 | P22735 | 1/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.46 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.46 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.46 |
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193297 | 0.92 | TGM2 (0.54) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL907356 | 0.91 | TGM2 (0.63) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3193614 | 0.90 | TGM2 (0.55) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3200867 | 0.87 | TGM2 (0.68) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL440756 | 0.83 | TGM2 (0.63) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3182349 | 0.83 | TGM2 (0.54) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3188863 | 0.82 | TGM2 (0.55) | TGM2LMNAF13A1TGM1TGM3 | |
| SCHEMBL3193313 | 0.82 | TGM2 (0.63) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3188716 | 0.81 | TGM2 (0.55) | TGM2THRATHRBLMNAF13A1 | |
| SCHEMBL3198431 | 0.81 | TGM2 (0.55) | TGM2THRATHRBLMNAF13A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101516896-B | Phosphate ester compound, metal salt thereof, dental material, and demtal composition | MITSU CHEMICALS INC | 2013-06-05 | — | — | CN | disclosed |
| US-20100024683-A1 | PHOSPHATE COMPOUND, METAL SALT THEREOF, DENTAL MATERIAL AND DENTAL COMPOSITION | MITSUI CHEMICALS, INC. (JP) | 2010-02-04 | — | — | US | disclosed |
| CN-101516896-A | Phosphate ester compound, metal salt thereof, dental material, and demtal composition | MITSUI CHEMICALS INC (JP) | 2009-08-26 | — | — | CN | disclosed |
| EP-2058318-A1 | PHOSPHATE ESTER COMPOUND, METAL SALT THEREOF, DENTAL MATERIAL, AND DENTAL COMPOSITION | Mitsui Chemicals, Inc. (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100024683-A1 | PHOSPHATE COMPOUND, METAL SALT THEREOF, DENTAL MATERIAL AND DENTAL COMPOSITION | CAD, PPIP5K2, SLC20A1 | TGM2 4191/4885THRA 4036/4885THRB 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.